ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
급성 관상동맥 증후군 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.5%를 나타내 134억 3,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 맞춤형 의료에 대한 수요, 인터벤셔널 심장병증 증가, 인지도의 향상, 세계적인 고령화에 기인하고 있습니다. 예측 기간의 주요 동향으로는 진단 도구의 진보, 의료 정보 기술의 통합, 신속한 대응 시스템, 기술의 진보 등이 있습니다.
향후 5년간의 성장률 6.5%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 0.4%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 독일과 일본에서 수입되는 심장 바이오마커 및 혈관성형술 장비의 비용을 증가시키고, 중요한 치료를 늦추거나, 환자의 치료비를 증가시킬 수 있기 때문에 미국 병원에 부담을 줄 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
급성 관상동맥 증후군 시장 성장은 관상동맥 질환, 허혈성 심장 질환, 혈관 질환과 같은 만성 질환의 유병률 증가로 촉진 될 것으로 예측됩니다. 관상동맥의 협착과 폐색을 특징으로 하는 허혈성 심장 질환은 그러한 만성 질환 중 하나입니다. 급성 관상동맥 증후군(ACS)의 치료는 특히 허혈성 심장 질환과 혈관 질환과 같은 환자의 경우 증상을 신속하게 완화하고 심장 손상을 최소화하고 추가 합병증을 예방하는 데 중점을 둡니다. 예를 들어, 2022년 8월에 Journal of the American College of Cardiology에 발표된 연구는 2025년부터 2060년까지 미국의 일반 인구 사이에서 4개의 심혈관 위험 인자가 모두 증가할 것으로 예측된다고 강조했습니다. 지질이상증은 27.6%, 고혈압은 25.1% 증가할 것으로 추정됩니다. 또한 심부전(33.4%), 허혈성 심질환(30.7%), 심근경색(16.9%), 뇌졸중(33.8%)도 크게 증가할 것으로 예상됩니다. 이것은 관상동맥 질환, 허혈성 심장 질환, 혈관 질환과 같은 만성 질환의 유행이 급성 관상동맥 증후군 시장 성장의 원동력임을 강조합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 급성 관상동맥 증후군 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 급성 관상동맥 증후군 시장 : 성장률 분석
세계의 급성 관상동맥 증후군 시장 실적 : 규모와 성장(2019-2024년)
세계의 급성 관상동맥 증후군 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 급성 관상동맥 증후군 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 급성 관상동맥 증후군 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
비ST 분절상승 심근경색증
ST 분절상승 심근경색증
불안정 협심증
세계의 급성 관상동맥 증후군 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
약물
스타틴
베타 차단제
ACE 억제제
항응고제
기타 치료
세계의 급성 관상동맥 증후군 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
스트레스 검사
혈액 검사
영상 검사
기타 진단
세계의 급성 관상동맥 증후군 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
비경구
세계의 급성 관상동맥 증후군 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타 최종 사용자
세계의 급성 관상동맥 증후군 시장 : 비ST 분절상승 심근경색증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
의학적 관리
경피적 관상동맥 중재술(PCI)
관상동맥 우회술(CABG)
세계의 급성 관상동맥 증후군 시장 : ST 분절상승 심근경색증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
의료 관리
경피적 관상동맥 중재술(PCI)
관상동맥 우회술(CABG)
세계의 급성 관상동맥 증후군 시장 : 불안정 협심증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
의학적 관리
경피적 관상동맥 중재술(PCI)
관상동맥 우회술(CABG)
제7장 지역별/국가별 분석
세계의 급성 관상동맥 증후군 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 급성 관상동맥 증후군 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
급성 관상동맥 증후군 시장 : 경쟁 구도
급성 관상동맥 증후군 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson and Johnson Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Siemens AG : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bayer AG
Novartis AG
Sanofi-Aventis LLC.
Bristol-Myers Squibb Company
Thermo Fisher Scientific Inc.
AstraZeneca PLC
Abbott Laboratories
Medtronic Plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Co Ltd.
Stryker Corporation
GE Healthcare Inc.
Boehringer Ingelheim International GmbH
Boston Scientific Corporation
Regeneron Pharmaceuticals Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
급성 관상동맥 증후군 시장(2029년) : 새로운 기회를 제공하는 국가
급성 관상동맥 증후군 시장(2029년) : 새로운 기회를 제공하는 부문
급성 관상동맥 증후군 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions resulting from a sudden reduction in blood flow to the heart. ACS is characterized by symptoms like chest pain or discomfort (angina), along with indicators of cardiac distress such as shortness of breath and dizziness. The primary objective in treating ACS is to swiftly alleviate symptoms, mitigate heart damage, and prevent potential complications.
There are three main types of acute coronary syndrome such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and unstable angina. NSTEMI denotes a type of heart attack where one or more coronary arteries are partially or completely obstructed, leading to reduced blood supply to the heart muscle. Treatment modalities encompass medications like statins, beta-blockers, ACE inhibitors, anticoagulants, among others. Diagnostic procedures include stress tests, blood tests, various imaging techniques, and more. These treatments can be administered orally or through parenteral routes, and they are employed across a range of end-users including hospitals, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The acute coronary syndrome market research report is one of a series of new reports from The Business Research Company that provides acute coronary syndrome market statistics, including acute coronary syndrome industry global market size, regional shares, competitors with an acute coronary syndrome market share, detailed acute coronary syndrome market segments, market trends and opportunities and any further data you may need to thrive in the acute coronary syndrome industry. This acute coronary syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.86 billion in 2024 to $10.43 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.
The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $13.43 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.
The forecast of 6.5% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers could strain U.S. hospitals by inflating the cost of cardiac biomarkers and angioplasty equipment imported from Germany and Japan, potentially delaying critical interventions and raising patient care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growth of the acute coronary syndrome market is expected to be fueled by the increasing prevalence of chronic diseases like coronary artery disease, ischemic heart disease, and vascular diseases. Ischemic heart disease, characterized by the narrowing or obstruction of coronary arteries, is one such chronic condition. The treatment of acute coronary syndrome (ACS) focuses on promptly alleviating symptoms, minimizing heart damage, and preventing further complications, especially for patients dealing with conditions like ischemic heart disease and vascular diseases. For instance, in August 2022 a study published in the Journal of the American College of Cardiology highlighted an anticipated rise in all four cardiovascular risk factors among the general U.S. population from 2025 to 2060. Dyslipidemia was projected to increase by 27.6%, while hypertension by 25.1%. The study also noted significant anticipated increases in rates of heart failure (33.4%) and ischemic heart disease (30.7%), followed by heart attacks (16.9%) and strokes (33.8%). This underscores how the prevalence of chronic diseases, including coronary artery disease, ischemic heart disease, and vascular diseases, is a driving force behind the acute coronary syndrome market's growth.
The growth of the acute coronary syndrome market is expected to be driven by rising healthcare expenditures. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities over a specific period, which can be measured at individual, community, national, or global levels. These expenditures are increasing due to factors such as the growing prevalence of chronic diseases, an aging population, advancements in medical technology, and a higher demand for more advanced healthcare services and treatments. As healthcare spending increases, it supports the development of improved diagnostic technologies, advanced therapies, and comprehensive treatment options, which are essential for addressing the growing need for cardiovascular care. For example, in May 2023, the Office for National Statistics reported that healthcare spending in the UK was approximately $362.08 billion (£292 billion), marking a 5.6% increase from the previous year. Additionally, long-term health and social care spending saw a real-term increase of 2.8% in 2022. As a result, rising healthcare expenditures will continue to fuel the growth of the acute coronary syndrome market.
The key players in the acute coronary syndrome market are focusing on the development of groundbreaking drugs to advance the treatment of acute coronary syndrome and maintain their market standing. These innovations in drug development have the potential to enhance the effectiveness of ACS treatment, streamlining the process for each patient in terms of time and resources. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, introduced Lodoco, the first anti-inflammatory atheroprotective cardiovascular treatment approved by the Food and Drug Administration (FDA). This medication is designed to reduce the risk of heart stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.
In May 2023, Avertix Medical Inc., a US-based company specializing in the development of implantable patient alerting systems for acute coronary syndrome (ACS), entered a merger agreement with BIOS Acquisition Corporation for an approximate sum of $195 million. This strategic merger positions Avertix to enhance its commercial portfolio and further advance its innovative products, providing both patients and healthcare providers with state-of-the-art tools. BIOS Acquisition Corporation is a US-based incorporated blank check company.
Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMerieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.
North America was the largest region in the acute coronary syndrome market in 2024. The regions covered in acute coronary syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute coronary syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Coronary Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute coronary syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute coronary syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute coronary syndrome market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acute Coronary Syndrome Market Characteristics
3. Acute Coronary Syndrome Market Trends And Strategies
4. Acute Coronary Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Acute Coronary Syndrome Growth Analysis And Strategic Analysis Framework
5.1. Global Acute Coronary Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acute Coronary Syndrome Market Growth Rate Analysis
5.4. Global Acute Coronary Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acute Coronary Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acute Coronary Syndrome Total Addressable Market (TAM)
6. Acute Coronary Syndrome Market Segmentation
6.1. Global Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-St-Elevation Myocardial Infarction
St-Elevation Myocardial Infarction
Unstable Angina
6.2. Global Acute Coronary Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Statins
Beta blockers
ACE inhibitors
Anticoagulants
Other Treatment
6.3. Global Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stress Test
Blood Tests
Imaging
Other Diagnosis
6.4. Global Acute Coronary Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.5. Global Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End User
6.6. Global Acute Coronary Syndrome Market, Sub-Segmentation Of Non-ST-Elevation Myocardial Infarction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medical Management
Percutaneous Coronary Intervention (PCI)
Coronary Artery Bypass Grafting (CABG)
6.7. Global Acute Coronary Syndrome Market, Sub-Segmentation Of ST-Elevation Myocardial Infarction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medical Management
Percutaneous Coronary Intervention (PCI)
Coronary Artery Bypass Grafting (CABG)
6.8. Global Acute Coronary Syndrome Market, Sub-Segmentation Of Unstable Angina, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medical Management
Percutaneous Coronary Intervention (PCI)
Coronary Artery Bypass Grafting (CABG)
7. Acute Coronary Syndrome Market Regional And Country Analysis
7.1. Global Acute Coronary Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acute Coronary Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
